Sugi Predict

Sugi Predict / Compounds / SCHEMBL938877

SCHEMBL938877

SCHEMBL938877

C#C[C@]1(CO)O[C@@H](n2ccc(N)nc2=O)CC1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3A Q14432 3/20 0.47
▸ LMNA P02545 3/20 0.47
▸ CACNA1F O60840 2/20 0.47
▸ ALB P02768 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ CACNA1D Q01668 2/20 0.47
▸ CACNA1S Q13698 2/20 0.47
▸ CACNA1C Q13936 2/20 0.47
▸ PDE4D Q08499 1/20 0.44
▸ SLC29A1 Q99808 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ MTOR P42345 1/20 0.44
▸ MDM2 Q00987 1/20 0.44
▸ NCOA1 Q15788 1/20 0.44
▸ NCOA3 Q9Y6Q9 1/20 0.44
▸ POLB P06746 1/20 0.41
▸ POLG P54098 2/20 0.37
▸ NT5E P21589 2/20 0.35
▸ POLA1 P09884 1/20 0.35
▸ P2RY2 P41231 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26135468 1.00 PDE3A (0.47) PDE3ALMNACACNA1FALBMAPT
SCHEMBL24695861 1.00 PDE3A (0.47) PDE3ALMNACACNA1FALBMAPT
SCHEMBL32670593 1.00 PDE3A (0.47) PDE3ALMNACACNA1FALBMAPT
SCHEMBL938876 1.00 PDE3A (0.47) PDE3ALMNACACNA1FALBMAPT
SCHEMBL9548789 0.90 PDE3A (0.48) PDE3ALMNACACNA1FALBMAPT
SCHEMBL9548796 0.90 PDE3A (0.48) PDE3ALMNACACNA1FALBMAPT
SCHEMBL26267576 0.87 PDE3A (0.46) PDE3ALMNACACNA1FALBMAPT
SCHEMBL31653097 0.87 PDE3A (0.46) PDE3ALMNACACNA1FALBMAPT
SCHEMBL20879387 0.85 LMNA (0.52) PDE3ALMNACACNA1FALBMAPT
SCHEMBL18877436 0.82 PDE3A (0.49) PDE3ALMNACACNA1FALBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020022722-A1 4'-C-ethynyl pyrimidine nucleoside compounds OHRUI HIROSHI (JP) 2002-02-21 — — US claimed
US-6291670-B1 VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-09-18 — — US claimed
EP-1928475-B1 ANTIVIRAL PHOSPHORAMIDATES OF 4'-C-AZIDO-SUBSTITUTED PRONUCLEOTIDES RIBOSCIENCE LLC (US) 2018-05-23 — — EP disclosed
EP-2361922-B1 Intermediate to HCV-Nucleoside Inhibitors JANSSEN PRODUCTS LP (US) 2012-08-22 — — EP disclosed
US-8158779-B2 Antiviral nucleosides MEDIVIR AB (SE) 2012-04-17 — — US disclosed
EP-2361922-A1 Intermediate to HCV-Nucleoside Inhibitors Medivir AB (SE) 2011-08-31 — — EP disclosed
US-20110172410-A1 ANTIVIRAL NUCLEOSIDES MEDIVIR AB (SE) 2011-07-14 — — US disclosed
US-7935681-B2 Antiviral nucleosides MEDIVIR AB (SE) 2011-05-03 — — US disclosed
US-20110015148-A1 ANTIVIRAL NUCLEOSIDES MEDIVIR AB (SE) 2011-01-20 — — US disclosed
EP-2084175-B1 HCV NUCLEOSIDE INHIBITOR MEDIVIR AB (SE) 2010-12-29 — — EP disclosed
US-7825239-B2 Antiviral nucleosides MEDIVIR AB (SE) 2010-11-02 — — US disclosed
US-20070042988-A1 Antiviral phosphoramidates ROCHE PALO ALTO LLC 2007-02-22 — — US disclosed
WO-2007020193-A2 ANTIVIRAL PHOSPHORAMIDATES OF 4 ' -SUBSTITUTED PRONUCLEOTIDES F. HOFFMANN-LA ROCHE AG (CH) 2007-02-22 — — WO disclosed
WO-2006021341-A1 ANTIVIRAL 4’-AZIDO-NUCLEOSIDES F. HOFFMANN-LA ROCHE AG (CH) 2006-03-02 — — WO disclosed
US-20060040890-A1 4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one; hepatitis C virus. ROCHE PALO ALTO LLC 2006-02-23 — — US disclosed
EP-1177201-B1 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES YAMASA CORP (JP) 2003-09-24 — — EP disclosed
US-6403568-B1 FOR THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) YAMASA CORPORATION (JP) 2002-06-11 — — US disclosed
US-20020022722-A1 4'-C-ethynyl pyrimidine nucleoside compounds OHRUI HIROSHI (JP) 2002-02-21 — — US disclosed
US-6333315-B1 FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-12-25 — — US disclosed
US-6291670-B1 VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172410-A1 ANTIVIRAL NUCLEOSIDES PNP, MTAP, UMPS PDE3A 620/4885LMNA 3285/4885CACNA1F 4866/4885
US-20070042988-A1 Antiviral phosphoramidates RPP30, RNASE1, ADORA2B PDE3A 794/4885LMNA 3990/4885CACNA1F 4773/4885
US-20020022722-A1 4'-C-ethynyl pyrimidine nucleoside compounds PNP, TYMP, NUDT1 PDE3A 648/4885LMNA 3211/4885CACNA1F 4076/4885
US-20060040890-A1 4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one; hepatitis C virus. HAVCR2, HCCS, CYP2S1 PDE3A 2084/4885LMNA 4413/4885CACNA1F 4747/4885
US-20110015148-A1 ANTIVIRAL NUCLEOSIDES PNP, MTAP, UMPS PDE3A 620/4885LMNA 3285/4885CACNA1F 4866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.